Selected research
Industry Research
Chemotheraphy-induced Nausea and Vomitting Treatment Industry Research Report 2026
Market perspective
The global Chemotheraphy-induced Nausea and Vomitting Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Chemotheraphy-induced Nausea and Vomitting Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Chemotheraphy-induced Nausea and Vomitting Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Chemotheraphy-induced Nausea and Vomitting Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Chemotheraphy-induced Nausea and Vomitting Treatment include Eisai, Merck & Co, GlaxoSmithKline, Tesaro, Orchid Healthcare, OPKO Health, Mylan Pharmaceuticals, Mundipharma and Heron Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Chemotheraphy-induced Nausea and Vomitting Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Chemotheraphy-induced Nausea and Vomitting Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chemotheraphy-induced Nausea and Vomitting Treatment Market by Company
Eisai
Merck & Co
GlaxoSmithKline
Tesaro
Orchid Healthcare
OPKO Health
Mylan Pharmaceuticals
Mundipharma
Heron Therapeutics
Helsinn
F.Hoffmann La Roche
Especificos Stendhal
Baxter Healthcare
Barr Laboratories
Aphios
Acacia Pharma
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Others
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Application
Delayed Nausea and Vomitting Treatment
Acute Nausea and Vomitting Treatment
Anticipatory Nausea and Vomitting Treatment
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemotheraphy-induced Nausea and Vomitting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotheraphy-induced Nausea and Vomitting Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5-HT3 Inhibitors
- NK1 Inhibitors
- Others
Applications
- Delayed Nausea and Vomitting Treatment
- Acute Nausea and Vomitting Treatment
- Anticipatory Nausea and Vomitting Treatment
Companies covered
- Eisai
- Merck & Co
- GlaxoSmithKline
- Tesaro
- Orchid Healthcare
- OPKO Health
- Mylan Pharmaceuticals
- Mundipharma
- Heron Therapeutics
- Helsinn
- F.Hoffmann La Roche
- Especificos Stendhal
- Baxter Healthcare
- Barr Laboratories
- Aphios
- Acacia Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Chemotheraphy-induced Nausea and Vomitting Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 5-HT3 Inhibitors
- 2.2.3 NK1 Inhibitors
- 2.2.4 Others
- 2.3 Chemotheraphy-induced Nausea and Vomitting Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Delayed Nausea and Vomitting Treatment
- 2.3.3 Acute Nausea and Vomitting Treatment
- 2.3.4 Anticipatory Nausea and Vomitting Treatment
- 2.4 Assumptions and Limitations
3 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type
- 3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2027-2032)
4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application
- 4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2021-2032)
- 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region
- 5.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
- 5.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
- 5.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
- 5.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
- 5.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue
- 6.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment Head Office and Area Served
- 6.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Players, Product Type & Application
- 6.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Manufacturers Established Date
- 6.6 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
- 7.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
- 7.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
- 8.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
- 8.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
- 10.2 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
- 10.4 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eisai
- 12.1.1 Eisai Company Information
- 12.1.2 Eisai Business Overview
- 12.1.3 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.1.4 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.1.5 Eisai Recent Developments
- 12.2 Merck & Co
- 12.2.1 Merck & Co Company Information
- 12.2.2 Merck & Co Business Overview
- 12.2.3 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.2.4 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.2.5 Merck & Co Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.3.4 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Tesaro
- 12.4.1 Tesaro Company Information
- 12.4.2 Tesaro Business Overview
- 12.4.3 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.4.4 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.4.5 Tesaro Recent Developments
- 12.5 Orchid Healthcare
- 12.5.1 Orchid Healthcare Company Information
- 12.5.2 Orchid Healthcare Business Overview
- 12.5.3 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.5.4 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.5.5 Orchid Healthcare Recent Developments
- 12.6 OPKO Health
- 12.6.1 OPKO Health Company Information
- 12.6.2 OPKO Health Business Overview
- 12.6.3 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.6.4 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.6.5 OPKO Health Recent Developments
- 12.7 Mylan Pharmaceuticals
- 12.7.1 Mylan Pharmaceuticals Company Information
- 12.7.2 Mylan Pharmaceuticals Business Overview
- 12.7.3 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.7.4 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.7.5 Mylan Pharmaceuticals Recent Developments
- 12.8 Mundipharma
- 12.8.1 Mundipharma Company Information
- 12.8.2 Mundipharma Business Overview
- 12.8.3 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.8.4 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.8.5 Mundipharma Recent Developments
- 12.9 Heron Therapeutics
- 12.9.1 Heron Therapeutics Company Information
- 12.9.2 Heron Therapeutics Business Overview
- 12.9.3 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.9.4 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.9.5 Heron Therapeutics Recent Developments
- 12.10 Helsinn
- 12.10.1 Helsinn Company Information
- 12.10.2 Helsinn Business Overview
- 12.10.3 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.10.4 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.10.5 Helsinn Recent Developments
- 12.11 F.Hoffmann La Roche
- 12.11.1 F.Hoffmann La Roche Company Information
- 12.11.2 F.Hoffmann La Roche Business Overview
- 12.11.3 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.11.4 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.11.5 F.Hoffmann La Roche Recent Developments
- 12.12 Especificos Stendhal
- 12.12.1 Especificos Stendhal Company Information
- 12.12.2 Especificos Stendhal Business Overview
- 12.12.3 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.12.4 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.12.5 Especificos Stendhal Recent Developments
- 12.13 Baxter Healthcare
- 12.13.1 Baxter Healthcare Company Information
- 12.13.2 Baxter Healthcare Business Overview
- 12.13.3 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.13.4 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.13.5 Baxter Healthcare Recent Developments
- 12.14 Barr Laboratories
- 12.14.1 Barr Laboratories Company Information
- 12.14.2 Barr Laboratories Business Overview
- 12.14.3 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.14.4 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.14.5 Barr Laboratories Recent Developments
- 12.15 Aphios
- 12.15.1 Aphios Company Information
- 12.15.2 Aphios Business Overview
- 12.15.3 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.15.4 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.15.5 Aphios Recent Developments
- 12.16 Acacia Pharma
- 12.16.1 Acacia Pharma Company Information
- 12.16.2 Acacia Pharma Business Overview
- 12.16.3 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2026)
- 12.16.4 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
- 12.16.5 Acacia Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst